Phase I expansion at Silvassa facility completed ahead of schedule
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lords Mark Industries has completed Phase I expansion at its Silvassa facility nearly three months ahead of the December 2026 deadline. The surgical and orthopaedic product portfolio grows from 36 to 54 SKUs with 18 new products. The expanded production line starts commercial operations on October 11, 2026. Existing 36 products hold US FDA approval; the new 18 SKUs await US FDA clearance expected before December 2026.
Positive. Early capacity ramp-up, wider product range, and US FDA pipeline may support revenue growth in coming quarters.